Asbestos exposure causes both mesothelioma and lung cancer, but they are different cancers in different tissues with different prognoses, different treatments, and different VA and trust fund rules. If you or your veteran has just been diagnosed and you are not sure which condition applies, the pathology report is what tells you. This page explains how the two differ medically, how the diagnoses are confirmed, what each means for VA benefits and asbestos trust fund claims, and where to go next.
If you already know which diagnosis applies, the relevant pillars are our mesothelioma resources for veterans or our asbestos lung cancer resources for veterans. Most of the practical filing process is the same. The differences below are what you need to know up front.
The fast comparison
| Feature | Mesothelioma | Asbestos lung cancer |
|---|---|---|
| Where it grows | In the mesothelium (the lining of the lungs, abdomen, heart, or testes) | In the lung tissue itself (bronchi, bronchioles, alveoli) |
| Cell types | Epithelioid (most common), sarcomatoid, biphasic | Adenocarcinoma, squamous cell, large cell, small cell |
| Asbestos cause | Almost always; mesothelioma is signature for asbestos | Can be; asbestos is one of multiple causes (smoking, radon, others) |
| Latency from first exposure | 20 to 60 years | 15 to 35 years |
| Smoking interaction | Not strongly affected by smoking | Multiplicative with smoking; both raise risk independently |
| VA rating during active disease | 100% under 38 CFR 4.97 DC 6819 | 100% under 38 CFR 4.97 DC 6819 (same code) |
| Trust fund tier | Highest (Level VIII or equivalent) | One or two tiers below mesothelioma; still substantial |
| Median 5-year survival | Approximately 10 to 12 percent | Varies widely by stage and type; 18 to 25 percent overall |
This is a fast comparison. The rest of the page expands each row.
Different cancers in different tissues
The most important medical difference is anatomical. Mesothelioma grows in the mesothelium, a thin layer of cells that lines the inside of the chest cavity (pleura), abdomen (peritoneum), or heart (pericardium). About 80 to 85 percent of mesothelioma cases are pleural (in the chest); the rest are peritoneal, pericardial, or testicular.
Asbestos lung cancer grows in the lung tissue itself: in the airways (bronchi and bronchioles) or in the air sacs (alveoli). It is medically the same disease as any other lung cancer, but caused at least in part by asbestos rather than (or in addition to) other risk factors.
This difference matters because the two cancers spread differently, present with different symptoms, and respond to different treatments.
How the diagnosis is confirmed
Both cancers are confirmed by tissue biopsy and pathology review. The pathology report uses different terminology for each.
Mesothelioma pathology
The report typically says “mesothelioma” explicitly and indicates the type (epithelioid, sarcomatoid, or biphasic). Confirmation often involves immunohistochemistry markers such as calretinin, WT-1, CK5/6, and D2-40 to distinguish mesothelioma from other cancers that can spread to the chest. If your report says “malignant pleural mesothelioma” or “malignant peritoneal mesothelioma,” that is the diagnosis.
Asbestos lung cancer pathology
The report says “lung cancer” or names the specific histology: “adenocarcinoma,” “squamous cell carcinoma,” “large cell carcinoma,” or “small cell lung cancer.” The pathology report alone does not confirm asbestos causation; the asbestos link is established through the patient’s exposure history. Some pathology reports note ferruginous bodies (microscopic markers of asbestos fiber retention in lung tissue) which strengthens the asbestos attribution. A history of asbestosis (asbestos-related lung scarring) on prior imaging is also strong evidence.
The smoking question
This is where the two cancers diverge sharply for veterans.
Mesothelioma is essentially specific to asbestos. Smoking is not a recognized cause of mesothelioma. A veteran with mesothelioma and any documented asbestos exposure during service has a clean causal chain for VA service connection. The smoking question rarely arises.
Asbestos lung cancer is more complicated because both asbestos and smoking are independent causes of lung cancer. The medical literature is clear that the two interact multiplicatively: a heavy smoker with asbestos exposure has a far higher lung cancer risk than either factor alone. The VA’s standard is that asbestos exposure during service must be at least as likely as not a contributing cause. In a veteran with documented military asbestos exposure, that standard is usually met regardless of smoking history. But smokers should expect the VA to look at the smoking history as part of the evaluation, and the medical opinion may need to address the relative contribution.
For practical purposes: a veteran who never smoked has a stronger lung cancer claim than a heavy smoker. But heavy smokers with documented asbestos exposure also win these claims regularly. The Veteran Service Officer files the claim and presents the evidence; the VA evaluates it on the evidence presented.
Latency
Mesothelioma latency is longer. The cancer usually develops 20 to 60 years after first exposure, with most cases in the 30 to 50 year window. A veteran who served in the 1960s and 1970s is now well within that window; a veteran who served in the 1980s and 1990s is approaching the early end.
Asbestos lung cancer latency is shorter, typically 15 to 35 years from first exposure. Lung cancer in a veteran who served as recently as the late 1990s could be plausibly asbestos-related if exposure is documented.
Prognosis
Both cancers have poor prognoses, but the numbers differ.
Mesothelioma has a median overall survival of about 12 to 18 months from diagnosis, with 5-year survival around 10 to 12 percent. Pleural mesothelioma (the most common type) has slightly worse outcomes than peritoneal. Outcomes have improved modestly with newer immunotherapy combinations (nivolumab plus ipilimumab) approved as first-line therapy.
Lung cancer outcomes vary widely by histology and stage at diagnosis. Non-small cell lung cancer (the more common form, including most adenocarcinomas and squamous cell carcinomas) has a 5-year survival of about 25 percent overall, with much better outcomes for early-stage disease (Stage I localized: ~65 percent 5-year survival) and much worse for late-stage (Stage IV metastatic: ~8 percent 5-year survival). Small cell lung cancer has worse overall outcomes, with 5-year survival around 7 percent.
Targeted therapies and immunotherapy have changed lung cancer outcomes more than mesothelioma outcomes over the past decade. EGFR, ALK, ROS1, and KRAS-G12C-targeted therapies; PD-L1 immunotherapy (pembrolizumab, atezolizumab); and combinations have meaningfully extended survival for subsets of lung cancer patients. Genomic testing of the tumor specimen is standard at diagnosis to identify which therapies apply.
Treatment
Mesothelioma treatment
- Surgery (extrapleural pneumonectomy or pleurectomy/decortication for pleural; cytoreductive surgery with HIPEC for peritoneal) for early-stage operable cases.
- Chemotherapy (cisplatin or carboplatin plus pemetrexed) as systemic treatment.
- Immunotherapy (nivolumab plus ipilimumab) as first-line treatment for unresectable or metastatic cases.
- Radiation in select cases.
- Clinical trials for novel agents.
Lung cancer treatment
- Surgery (lobectomy, pneumonectomy, wedge resection) for operable early-stage non-small cell lung cancer.
- Chemotherapy (platinum-based combinations).
- Targeted therapy guided by tumor genomic testing.
- Immunotherapy (PD-L1 checkpoint inhibitors), often in combination with chemotherapy.
- Radiation, including stereotactic body radiation therapy (SBRT) for inoperable early-stage tumors.
- Clinical trials.
Treatment for both cancers is best coordinated through a multidisciplinary thoracic oncology team. The VA medical centers with thoracic oncology programs (Houston, Dallas, Long Beach, Boston, and others) treat both. Private cancer centers including MD Anderson, Memorial Sloan Kettering, and Dana-Farber also see large volumes of both cancers.
What the VA pays
For active disease, the VA disability rating is the same: 100 percent under 38 CFR 4.97 Diagnostic Code 6819, while the cancer is active and for 6 months after the cessation of treatment. This applies to both mesothelioma and asbestos lung cancer.
Monthly compensation at the 100 percent rate is approximately:
- $3,831 for a veteran alone.
- $4,044 for a veteran with spouse.
- $4,191 for a veteran with spouse and 1 child.
Special Monthly Compensation may apply on top of the 100 percent rating if daily aid and attendance is needed (about $4,800 for SMC L). See VA disability rating and VA Aid and Attendance.
For the surviving spouse, Dependency and Indemnity Compensation (DIC) pays approximately $1,653 per month tax-free regardless of which cancer caused the death. See DIC survivor benefits.
What the trust funds pay
Asbestos trust funds use a tiered scheduled-value system. Mesothelioma is the highest tier; lung cancer with documented asbestos exposure is one or two tiers below.
For mesothelioma, individual trust fund payouts can range from approximately $20,000 to $100,000 per trust depending on the trust, exposure documentation, and disease severity. A well-documented mesothelioma case can have legitimate claims against multiple trusts.
For asbestos lung cancer, individual trust fund payouts are typically lower per trust because the disease is one or two tiers down on most trust schedules. Some trusts also reduce payouts for heavy smokers or require additional medical documentation linking the lung cancer specifically to asbestos rather than smoking. Even at the lower tier, total payouts across multiple trusts can be substantial.
Each trust has its own rules about smoking history, asbestosis prerequisite, and exposure threshold for lung cancer claims. The trust fund analysis is done by an asbestos trust fund attorney, typically on contingency, with no up-front cost to the family. See asbestos trust funds for veterans for more detail.
If you have asbestosis with no cancer yet
Asbestosis (asbestos-related lung scarring without cancer) is itself a service-connectable condition under VA rules. A veteran with diagnosed asbestosis but no cancer can file a VA disability claim for the asbestosis based on pulmonary function impairment, typically rated at 10 to 60 percent depending on severity.
If lung cancer subsequently develops, the cancer is treated as a secondary condition under 38 CFR 3.310 (secondary service connection), and the VA usually awards 100 percent at that point. This is a well-established pathway and the VSO can file the supplemental claim quickly when a new cancer diagnosis comes in.
Asbestosis also strengthens any future trust fund claims because it is independent radiographic and clinical evidence of asbestos disease.
How to figure out which one you have
The pathology report is the answer. Ask the diagnosing physician for a complete copy. The report will name the cancer specifically. Common phrasings:
- “Malignant pleural mesothelioma, epithelioid type” → mesothelioma.
- “Adenocarcinoma of the lung, right upper lobe” → lung cancer.
- “Squamous cell carcinoma of the bronchus” → lung cancer.
- “Small cell lung cancer” → lung cancer.
- “Pleural plaques with calcification” → not cancer; this is asbestos-related pleural disease, which is itself service-connectable but does not by itself qualify as cancer.
If the report says “adenocarcinoma of unknown primary” or otherwise does not specify the origin, the diagnosing oncologist is the right person to clarify. Mesothelioma and adenocarcinoma of the lung can sometimes look similar on initial imaging; immunohistochemistry distinguishes them.
Where to go from here
If your veteran has mesothelioma
Start at the veterans hub and read VA benefits for mesothelioma. The full meso silo (Navy exposure, shipyard exposure, base exposure, trust funds, statistics) covers what you need.
If your veteran has asbestos-related lung cancer
Read asbestos lung cancer in veterans. The VA filing process and trust fund analysis are similar to mesothelioma; the page covers the lung-cancer-specific differences.
If you are not sure yet
Ask the diagnosing physician for a complete pathology report and read the histology line. If you cannot reach the physician, the hospital’s medical records department can release the report to the patient or authorized family member.
If your veteran has died and you need to figure out what was actually documented
The death certificate and the most recent treatment records will say what was diagnosed. Hospital medical records are available to the executor of the estate or, in many states, to the surviving spouse.
Related resources
- Veterans hub (orientation page)
- Asbestos lung cancer in veterans (the full pillar)
- VA benefits (covers both)
- How to file a VA claim
- VA disability rating
- VA Aid and Attendance
- DIC survivor benefits
- Asbestos trust funds for veterans
- Navy veteran asbestos exposure
- Shipyard asbestos exposure
- Military base asbestos exposure
- About Larry Gates, our Client Advocate
If you have questions about which cancer your veteran has, what each means for VA benefits, or how trust fund claims work for your situation, you can call the office at (800) 763-9692. The phone line is staffed during business hours. For specific medical questions, the diagnosing oncologist is the right person to ask. For specific legal questions about trust fund eligibility, consult a qualified asbestos trust fund attorney.
Have questions about your situation?
Call to speak with someone who can point you to the right Veteran Service Officer, walk you through what evidence you need, or explain how the trust fund pathway works alongside your VA claim. There is no cost and no obligation. We do not handle your VA claim ourselves; we help families understand the parallel benefit pathways that most veterans never claim.
Call (800) 763-9692 Phone line staffed during business hours.